GENFIT (NASDAQ:GNFT) Stock Price Up 0.7% - Time to Buy?

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Get Free Report)'s stock price was up 0.7% on Wednesday . The company traded as high as $3.81 and last traded at $3.71. Approximately 694 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 10,456 shares. The stock had previously closed at $3.68.

GENFIT Trading Down 2.7%

The stock's 50 day moving average price is $4.10 and its two-hundred day moving average price is $3.80. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.08.

Institutional Trading of GENFIT

A hedge fund recently bought a new stake in GENFIT stock. OLD Mission Capital LLC purchased a new stake in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,238 shares of the company's stock, valued at approximately $76,000. 2.24% of the stock is currently owned by institutional investors.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.